Navigation Links
'Clinical and Economical Considerations For IV Push Drug Delivery' by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Professional Use
Date:12/27/2007

ENGLEWOOD, Colo., Dec. 27 /PRNewswire/ -- The "Clinical and Economical Considerations For IV Push Drug Delivery" technical paper -- authored by Industry Expert Richard Rosenfeld, RPh, MBA, for Baxa Corporation -- is now accessible at http://expert411.com/_wsn/page16.html for media and professional reference. The paper is an overview of the historical background for IV push and a model for implementation of a successful program.

IV push of cephalosporin antibiotics and other drugs is an alternative method of administration that can be safe, efficacious and cost effective. This paper concentrates on IV push of cefazolin as a case study, since it is a high-use cephalosporin with physical and chemical properties similar to other drugs that can be administered by the IV push method.

Rosenfeld has personally implemented the use of IV push antibiotics within two hospital systems. During the first year that this IV push program was in place, more than 50,000 doses of cefazolin were administered by the IV push method with no occurrences of phlebitis or adverse drug events directly associated with the change in the administration method of this drug. The paper discusses the economical advantages of moving to IV push, as well as the resulting nurse satisfaction and patient benefits seen through the resulting research followup.

Executive Director of Pharmacy Management for the Scripps Health Hospital System in San Diego, CA, Rosenfeld has responsibility for all system pharmacy services through his position with Cardinal Technology and Services. Prior to joining the Scripps Health team, he served as a consultant at Sharp Healthcare, a five-hospital IDN in San Diego, California, where the IV push method of administration for cephalosporins was implemented.

Rosenfeld earned a BS in Pharmacy from Ferris State University and a BA in Chemistry from San Diego State University. He holds
'/>"/>

SOURCE Baxa Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... --  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) ... 35 th Annual Health Care Conference on Tuesday, March ... .  Lexicon management will provide an overview of Lexicon,s ... the presentation will be available through Lexicon,s website at ... available at www.lexpharma.com until April 3, 2015. ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015 CytomX, ... of cancer, today announced that Sean McCarthy , ... overview at the upcoming Cowen and Company 35 th ... . Dr. McCarthy,s presentation will take place at ... About CytomX Therapeutics CytomX Therapeutics develops Probody™ therapeutics ...
(Date:2/26/2015)... 2015 Caris Life Sciences® today announced ... Genitourinary Cancers Symposium in Orlando, Fla. ... tumor profiling. Both studies utilized Caris Molecular Intelligence™, ... identify biomarkers that shed light on potential treatment ... bladder cancer (SCBC). In one ...
(Date:2/25/2015)... Technologies Inc. (TSX-V: RTI) (the "Corporation") announced today that ... quarter of its fiscal year ended March 31, 2015. ... the CEO & CFO certifications for the three and ... on www.SEDAR.com . CFO ... pleased to announce the appointment of Prakash Hariharhan as ...
Breaking Biology Technology:Lexicon To Present At The Cowen 35th Annual Health Care Conference 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 3Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 4Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 5Radient Technologies Inc. Releases Third Quarter Results and Appoints New Interim CFO 2
... CRY ), a,biomaterials, medical device and tissue processing company, ... Annual Piper Jaffray Health,Care Conference at The New York Palace ... Anderson, president and chief executive officer of CryoLife,Inc., will provide ... 2:30 p.m. Eastern Time. , ...
... The Global Probiotics Council,(GPC), a committee formed ... the availability of two grants for the second ... Each Young,Investigator Grant will provide $50,000 over one ... role of probiotics and gastrointestinal microbiota in health,and ...
... Queen,s University Belfast is to become the United Kingdom,s ... ,cyber-attacks, after a funding boost from the Engineering and ... the EPSRC will help fund a new Innovation and ... (CSIT) - which will be based at Queen,s Institute ...
Cached Biology Technology:CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference 2New Young Investigator Grants for Probiotics Research Announced 2New Young Investigator Grants for Probiotics Research Announced 3New Young Investigator Grants for Probiotics Research Announced 4Queen's secures £25M for UK's cyber safety 2
(Date:2/24/2015)... 24, 2015 Research and Markets ... the "Global 2D Gesture Recognition Market 2015-2019" ... The analysts forecast the Global 2D Gesture Recognition ... over the period 2014-2019 The increased ... is one of the major trends in the ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... first time, scientists have shown that amniotic fluid (the ... new source of stem cells for therapeutic applications. The ... Blood , the official journal of the American ... other scientists, our research team wondered whether stem cells ...
... that its latest journal, Disease Models & Mechanisms ... MEDLINE. MEDLINE (http://www.pubmed.gov) is the premier bibliographic database of ... National Institutes of Health (NIH), MEDLINE contains over 16 million ... DMM has been recommended for inclusion by ...
... Md. (Mar. 31, 2009) Octogenarian women were unable to ... targeted at strengthening the thigh muscle, according to a ... . The results are surprising because previous studies have ... for people who are into their 70s. An increase ...
Cached Biology News:Amniotic fluid may provide new source of stem cells for future therapies 2Amniotic fluid may provide new source of stem cells for future therapies 3Disease Models & Mechanisms -- selected for indexing in Medline 2As good as it gets: Octogenarian muscles don't get stronger with exercise 2As good as it gets: Octogenarian muscles don't get stronger with exercise 3
Homo sapiens olfactomedin 1, transcript variant 3...
... agarose-digesting enzyme isolated from Pseudomonas atlantica. ... in agarose producing carbohydrate molecules that ... carbohydrate molecules will not interfere with ... Gelzyme enzyme can be used for ...
... the cellular components necessary for protein synthesis ... termination factors) but has not been treated ... primarily for the isolation of these components ... globin mRNA. Untreated Lysate is prepared from ...
...
Biology Products: